The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of drug-related polymorphisms with palbociclib-related neutropenia: Pharmacogenetic analysis of PALOMA-2/-3 (P2/3).
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst)
 
Olivia Fletcher
No Relationships to Disclose
 
Yuan Liu
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Yoshiko Umeyama
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Zhe Zhang
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Patrick Schnell
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Jean-Claude Marshall
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jillian G. Johnson
Stock and Other Ownership Interests - Pfizer
 
Linda S. Wood
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Masakazu Toi
Honoraria - AstraZeneca; Bayer; C & C Research Laboratories; Chugai Pharma; Daiichi Sankyo; Eisai; Genomic Health; Konica Minolta; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Pfizer; Sanofi; Shimadzu; Taiho Pharmaceutical; TAKEDA; Yakult Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Kyowa Hakko Kirin; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Lilly; Pfizer
Research Funding - AFI technology; Astellas Pharma (Inst); AstraZeneca; C & C Research Laboratories; Chugai Pharma; Daiichi Sankyo (Inst); Eisai; Japan Breast Cancer Research Group (Inst); Ono Pharmaceutical; Pfizer; Shimadzu (Inst); Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - JP 2017-143763 WO2017/131162A1 (Inst); PCT/JP2016/004374 (Inst)
Travel, Accommodations, Expenses - Genomic Health; Lilly
Other Relationship - Japan Breast Cancer Research Group; Japan Breast Cancer Research Group; Kyoto Breast Cancer Research Network; Organization for Oncology and Translational Research
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Novartis
 
Massimo Cristofanilli
Honoraria - Pfizer
Consulting or Advisory Role - CytoDyn; Merus; Novartis
 
Nicholas C. Turner
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Tesaro
Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Pfizer (Inst); Roche (Inst)
 
Cynthia Huang Bartlett
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer